Handbook of Clinical medicine

with warfarin, calcineurin 4 months continuation inhibitors, oestrogens, phenytoin; body secre- tions coloured orange-red (includes contact lens staining); altered liver function. Isoniazid 2 months intensive Inhibits formation of active pyridoxine (Vit B6) 4 months continuation which causes a peripheral neuropathy (risk with DM, CKD, HIV, malnutrition)  give with prophylactic pyridoxine; hepatitis. Pyrazinamide 2 months intensive Idiosyncratic hepatotoxicity, dose if eGFR<30. Ethambutol 2 months intensive Colour blindness, visual acuity, optic neuritis. Check visual acuity at start of treatment, moni- tor for symptoms. Monthly visual check if treat- ment > 2 months. Monitor levels if eGFR<30. __OOHHCCMM__1100ee..iinnddbb 339944 0022//0055//22001177 1199::0077 sesaesid suoitcefnI Latent TB 395 Balance the risk of development of active disease with the possible side-eff ects of treatment. Consider treatment in all at risk of active disease: HIV, transplantation, chemotherapy, biological agents eg anti-TNF (see p265), diabetes, CKD including di- alysis, silicosis, bariatric surgery, and recent close contact with pulmonary/laryngeal TB. Off er HIV, hepatitis B and C testing prior to treatment. Treat with 3 months of isoniazid (with pyridoxine) and rifampicin OR 6 months of isoniazid (with pyridoxine). If concerns about hepatotoxicity then 3 months of isoniazid and rifampicin may be preferred. In severe liver disease, seek specialist
